Ardeparin Pathway


Ardeparin binds to antithrombin III, accelerating its activity and inactivating factor Xa and thrombin, thereby inhibiting thrombosis. Ardeparin also binds to heparin cofactor II, inhibiting thrombin. Ardeparin does not effect prothrombin time (PT) assays and may prolong activated partial thromboplastin time (APTT). Ardeparin has double the anti-factor Xa activity of anti-factor IIa activity, compared to unfractionated heparin which has approximately equal anti-factor Xa activity and anti-factor IIa activity.

Pathway legend Zoom in

Pathway Image

Pathway legend Zoom in

References

  1. Jennings, L.K., & Saucedo, J.F. (2008). Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes. Current Opinion in Cardiology, 23(4), 302-308. PMID: 18520712
  2. Walker, C.P., & Royston, D. (2002). Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies. British Journal of Anaesthesia, 88(6), 848-863. PMID: 12173205